Associate Professor, Neurology, Emory University School of Medicine
Internal Medicine
Dr. Manuel Yepes, MD
|
|
Give Review
Doctor Manuel Yepes, MD is an expert in the field of Internal Medicine. Manuel Yepes is a published doctor. He has 52 publications published. The most current publication "ASPECTS decay during inter-facility transfer predicts patient outcomes in endovascular reperfusion for ischemic stroke: a unique assessment of dynamic physiologic chan..."
Publications
- ASPECTS decay during inter-facility transfer predicts patient outcomes in endovascular reperfusion for ischemic Stroke: a unique assessment of dynamic physiologic chan...
- Tissue-type plasminogen activator mediates neuroglial coupling in the central nervous system.
- Tissue-type plasminogen activator mediates neuronal detection and adaptation to metabolic stress.
- Tissue-type plasminogen activator protects neurons from excitotoxin-induced cell death via activation of the ERK1/2-CREB-ATF3 signaling pathway.
- Tissue-Type Plasminogen Activator Regulates the Neuronal Uptake of Glucose in the Ischemic Brain.
- Is magnetic resonance spectroscopy superior to conventional diagnostic tools in hypoxic-Ischemic encephalopathy?
- TWEAK and Fn14 in the Neurovascular Unit.
- Recurrent hematuria in a patient with a history of anaphylactic reaction to radiographic contrast.
- Transient diffusion-weighted imaging changes in a patient with reversible leukoencephalopathy syndrome.
- Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate Cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activati...
- Neuroserpin reduces Cerebral infarct volume and protects neurons from ischemia-induced apoptosis.
- [Thrombolytics and neuroprotective agents in the treatment of the patient with an acute Cerebrovascular ischemic accident].
- Identification of a novel small molecule HIF-1alpha translation inhibitor.
- Microglial low-density lipoprotein receptor-related protein 1 mediates the effect of tissue-type plasminogen activator on matrix metalloproteinase-9 activity in the is...
- Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate rece...
- Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons.
- Age and albumin D site-binding protein control tissue plasminogen activator levels: neuroToxic impact.
- The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors.
- The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic Brain.
- Tissue-type plasminogen activator in the ischemic Brain: more than a thrombolytic.
- Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic Brain.
- Activation of PDGF-CC by tissue plasminogen activator impairs blood-Brain barrier integrity during ischemic stroke.
- Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1.
- Regulated intramembrane proteolysis of the low-density lipoprotein receptor-related protein mediates Ischemic cell death.
- Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase.
- Neuroserpin polymorphisms and Stroke risk in a biracial population: the Stroke prevention in young women study.
- TWEAK and the central nervous system.
- Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein mediate Cerebral ischemia-induced nuclear factor-kappaB pathway activation.
- Tweak and FN14 in central nervous system health and Disease.
- Inhibition of TWEAK activity as a new treatment for inflammatory and degenerative Diseases.
- Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit.
- TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during Cerebral ischemia.
- Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation.
- Constipation heralding neuroborreliosis: an atypical tale of 2 patients.
- A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of Cerebral ischemia.
- LRAD3, A Novel Low-Density Lipoprotein Receptor Family Member That Modulates Amyloid Precursor Protein Trafficking.
- Tissue-type plasminogen activator has a neuroprotective effect in the ischemic Brain mediated by neuronal TNF-?.
- Phosphoinositide 3-kinase enhancer regulates neuronal dendritogenesis and survival in neocortex.
- Neuroserpin protects neurons from ischemia-induced plasmin-mediated cell death independently of tissue-type plasminogen activator inhibition.
- Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus.
- A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone.
- The interaction between tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 promotes the recruitment of neutrop...
- Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system.
- Tissue-type plasminogen activator induces opening of the blood-Brain barrier via the LDL receptor-related protein.
- Progressive ankylosis (Ank) protein is expressed by neurons and Ank immunohistochemical reactivity is increased by limbic seizures.
- Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic Stroke.
- Association between conformational mutations in neuroserpin and onset and severity of Dementia.
- Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent.
- New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system.
- Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system?
- Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors.
Schools
Pontificia Universidad Javeriana Facultad De Medicina
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Alzheimer's Disease
- Autonomic Disorders
- Brain Aneurysm
- Carotid Artery Disease
- View All
Doctors Specialties
- Vascular Neurology
- Internal Medicine
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Choice HMO
- Blue Choice Option POS
- Blue Open Access POS
- Blue Choice Advantage
- Blue Choice Network POS
- Blue Preferred PPO
- CareFirst Maryland POS
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Coventry Health Care
- Health Alliance
- Choice Care PPO
- Preferred PPO
- Kaiser Permanente
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Helpful Reviews
Similar Doctors
|
|
Dr. Efe Efemini, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas A. Peterman, MD |
|
|
Dr. Scott Steinbach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristin R. Wise, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bradley R. Bowman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy Wright, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shyian Jen, MD |
|
|
Dr. Kumiko Owada, MD |
|
|
Dr. Srikant Rangaraju, MD |